TY - JOUR
TI - Peanut-induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry
AU - Maris, I.
AU - Dölle-Bierke, S.
AU - Renaudin, J.-M.
AU - Lange, L.
AU - Koehli, A.
AU - Spindler, T.
AU - Hourihane, J.
AU - Scherer, K.
AU - Nemat, K.
AU - Kemen, C.
AU - Neustädter, I.
AU - Vogelberg, C.
AU - Reese, T.
AU - Yildiz, I.
AU - Szepfalusi, Z.
AU - Ott, H.
AU - Straube, H.
AU - Papadopoulos, N.G.
AU - Hämmerling, S.
AU - Staden, U.
AU - Polz, M.
AU - Mustakov, T.
AU - Cichocka-Jarosz, E.
AU - Cocco, R.
AU - Fiocchi, A.G.
AU - Fernandez-Rivas, M.
AU - Worm, M.
AU - Network for Online Registration of Anaphylaxis (NORA)
JO - Allergy: European Journal of Allergy and Clinical Immunology
PY - 2021
VL - 76
TODO - 5
SP - 1517-1527
PB - John Wiley and Sons Inc
SN - null
TODO - 10.1111/all.14683
TODO - antihistaminic agent;  beta 2 adrenergic receptor stimulating agent;  corticosteroid;  epinephrine;  food allergen;  epinephrine, adolescent;  anaphylaxis;  Article;  asthma;  cashew nut;  child;  child hospitalization;  cohort analysis;  comorbidity;  disease registry;  disease severity;  drug self administration;  egg allergy;  emergency treatment;  European;  European Anaphylaxis Registry;  female;  hazelnut;  human;  major clinical study;  male;  milk allergy;  nut allergy;  peanut allergy;  preschool child;  school child;  tertiary care center;  anaphylaxis;  Arachis;  peanut allergy;  register, Adolescent;  Anaphylaxis;  Arachis;  Child;  Epinephrine;  Humans;  Peanut Hypersensitivity;  Registries
TODO - Background: Peanut allergy has a rising prevalence in high-income countries, affecting 0.5%–1.4% of children. This study aimed to better understand peanut anaphylaxis in comparison to anaphylaxis to other food triggers in European children and adolescents. Methods: Data was sourced from the European Anaphylaxis Registry via an online questionnaire, after in-depth review of food-induced anaphylaxis cases in a tertiary paediatric allergy centre. Results: 3514 cases of food anaphylaxis were reported between July 2007-March 2018, 56% in patients younger than 18 years. Peanut anaphylaxis was recorded in 459 children and adolescents (85% of all peanut anaphylaxis cases). Previous reactions (42% vs. 38%; p = .001), asthma comorbidity (47% vs. 35%; p < .001), relevant cofactors (29% vs. 22%; p = .004) and biphasic reactions (10% vs. 4%; p = .001) were more commonly reported in peanut anaphylaxis. Most cases were labelled as severe anaphylaxis (Ring&Messmer grade III 65% vs. 56% and grade IV 1.1% vs. 0.9%; p = .001). Self-administration of intramuscular adrenaline was low (17% vs. 15%), professional adrenaline administration was higher in non-peanut food anaphylaxis (34% vs. 26%; p = .003). Hospitalization was higher for peanut anaphylaxis (67% vs. 54%; p = .004). Conclusions: The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition. © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
ER -